Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.
By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.
Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.
Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.
Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.
A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.
Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?October 04, 2018
In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.
Survival rates for pancreatic cancer should be stratified by disease subgroup to better reflect prognostic differences across the subgroups in this category.
The local delivery of cancer medications, via microparticles, is being explored in pancreatic cancer.
The bacterial strains found in oral samples may be representative of the types of strains that exist in the tumor microbiomes of patients with pancreatic or GI disease.
Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.
Preclinical data suggest that a BET inhibitor plus a PARP inhibitor may be a promising new approach to treat pancreatic cancer.
Different KRAS mutations may be associated with differing primary tumor locations and patterns of local recurrence in resected pancreatic cancer.
Pancreatic risk rises in a dose-response manner with increasing number of affected first-degree relatives.
Molecular features of primary and metastatic PDAC may provide new insight into disease management and drug development.
Researchers describe SuperCT, a predictive framework for the identification of tumor stromal cell type based on scRNA-seq data.
New-onset diabetes, but not baseline diabetes, is associated with an increased risk of progression of intraductal papillary mucinous neoplasms.
Organoids propagated from pancreatic tumor cells may provide a platform to evaluate patient response to immune checkpoint inhibitors.
The Moffitt gene set identifies a poor prognostic group of patients with locally advanced or metastatic pancreatic cancer.
Organoids can be propagated from CTCs from patients with pancreatic cancer, potentially offering an approach to study treatment resistance.
More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.
There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.
Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.
The development of BRCA-targeted therapies might offer the best opportunities to bring pancreatic cancer into the precision-oncology era.
Investigators assessed the association of hepatitis B infection and pancreatic cancer, along with predictors of pancreatic cancer and mortality.
Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.
New-onset adult diabetes mellitus appears to be both a risk factor for and a sequelae of pancreatic cancer.
Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.
Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.
Researchers identified potential targets for a companion diagnostic tests using poly-ligand profiling (PLP) to determine which patients with locally advanced or metastatic pancreatic cancer may benefit from gemcitabine plus evofosfamide.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Changes in Renal Cell Carcinoma Pathologic Staging and Histologic Grading
- Study Identifies Patients With Breast Cancer Who Don't Benefit From Adjuvant Chemo
- CD19 CAR T-Cell Therapies: "Expect an Evolution"
- Hypofractionated WBI Found Noninferior to Conventionally Fractionated WBI
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified